Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $14.00 Average PT from Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been assigned an average recommendation of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $14.00.

A number of equities analysts have issued reports on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley cut their price target on Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th. Wall Street Zen upgraded Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $12.00 target price on shares of Bicycle Therapeutics in a research note on Thursday, April 30th.

Bicycle Therapeutics Trading Down 0.9%

Bicycle Therapeutics stock opened at $4.18 on Tuesday. Bicycle Therapeutics has a 1 year low of $3.92 and a 1 year high of $9.18. The company has a market cap of $291.81 million, a PE ratio of -1.33 and a beta of 1.55. The company’s 50-day moving average is $4.31 and its two-hundred day moving average is $5.12.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. Research analysts forecast that Bicycle Therapeutics will post -1.97 EPS for the current year.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 5,905 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the sale, the chief executive officer directly owned 605,408 shares of the company’s stock, valued at $2,585,092.16. This represents a 0.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 9,977 shares of company stock valued at $42,702. Corporate insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Armistice Capital LLC raised its holdings in Bicycle Therapeutics by 8.7% in the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock worth $22,911,000 after purchasing an additional 258,000 shares during the period. Long Focus Capital Management LLC grew its holdings in shares of Bicycle Therapeutics by 7.7% in the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock valued at $10,981,000 after buying an additional 101,402 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Bicycle Therapeutics in the 4th quarter valued at $954,000. Flax Pond Capital LLC bought a new stake in shares of Bicycle Therapeutics in the 4th quarter valued at $1,229,000. Finally, Eversept Partners LP increased its position in shares of Bicycle Therapeutics by 6.6% in the 1st quarter. Eversept Partners LP now owns 190,715 shares of the company’s stock valued at $885,000 after buying an additional 11,800 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.